Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Focus on SVR hinders Merck's Victrelis' German benefit review; may impact Janssen

This article was originally published in Scrip

Executive Summary

Merck & Co's hepatitis C drug, Victrelis (boceprevir), appears to offer some additional benefit for patients who have not yet developed liver cirrhosis, but the extent of the benefit is uncertain, says IQWiG, Germany's Institute for Quality and Efficiency in Healthcare (IQWiG). Meanwhile, Janssen-Cilag, which markets competitor drug Incivo (telaprevir) is likely to be taking note, particularly given the institute's approach to sustained virological response (SVR) as an outcome. Work on an assessment of Incivo has already begun.

You may also be interested in...

German Insurers Want End To Free Pricing In Amnog Review

Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.

Investors Spooked By High Prices For Advanced Therapies

To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.

Cost Offsets Crucial For Uptake Of Advanced Therapies

To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts